Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass. & ZUG, Switzerland--(BUSINESS WIRE)--Moderna and Medison Pharma partner to commercialize Moderna's COVID-19 vaccine across Central Eastern Europe and Israel.

Moderna and Medison Pharma Partner to Commercialize Moderna's COVID-19 Vaccine Across Central Eastern Europe and Israel

Shares of Moderna Inc. rose 0.5% in premarket trading Monday, after the biotechnology company said it had submitted for conditional market approval (CMA) with the European Medicines Agency (EMA) for its COVID-19 vaccine in adolescents, ages 12 to less than 18. In May, the company said the Phase 2/3 study of its vaccine in adolescents met its primary immunogenicity endpoint.

Moderna submits for marketing approval of COVID-19 vaccine in adolescents in Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna files for authorization with Health Canada for its COVID-19 vaccine in adolescents.

Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna files for conditional marketing approval for its COVID-19 vaccine in adolescents in the European Union.

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

BioNTech SE

Pfizer

Pretty well, although it's not an apples-to-apples comparison between the two studies.

How Did Moderna's COVID Vaccine Results in Teens Stack Up Against Pfizer's?

The need for incentives for vaccination now could point to lower vaccination rates going forward.

Could COVID Vaccination Incentives Hint at Future Problems for Pfizer and Moderna?

How much better could things get for Moderna Inc. (MRNA)? A lot, it seems.

Moderna Sales Could Be Even Better in 2022

The biotech is poised to profit in both Japan and South Korea.

How Significant Are Moderna's Asian Regulatory Wins?

An effort now could guarantee vaccine delivery later.

Moderna Is Doing This to Avoid a Major Risk on the Horizon

It has to do with individuals who haven't yet been vaccinated.

This 1 Factor May Mean Bigger Vaccine Orders for Pfizer and Moderna

Moderna, Inc. (MRNA) Management Presents at Jefferies Virtual Healthcare Conference Call Transcript

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as investors see tremendous potential in leveraging mRNA technology beyond Covid, to fight a variety of.

Moderna Or BioNTech: Which mRNA Stock Should You Pick?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement to supply the Republic of Botswana with its COVID-19 vaccine.

Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine

Investors are only starting to appreciate the company's wild growth ride.

Moderna's About to Look Like a Value Stock

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 5% at $194.22 Wednesday morning amid continued vaccine optimism. The company announced an agreement with Thermo Fisher Scientific for fill/finish manufacturing of Moderna's COVID-19 vaccine, and a new drug substance production agreement with Lonza.

Why Is Moderna Stock Moving Today?

Moderna stock has rallied by almost 15% over the last week (five trading days), outperforming the S&P 500 which was up by just over 1% over the same period. The rally comes as Moderna's Covid-19 shot saw strong efficacy results (93% to 100%) from clinical trials conducted on children aged.

Will The Gains In Moderna Stock Continue?

Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.

Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine

The National Institutes of Health said Tuesday it plans to test booster shots from different vaccines in a fully vaccinated population as part of a "mix-and-match" clinical trial. The Phase 1/2 study is being funded by the National Institute of Allergy and Infectious Diseases.

U.S. to run 'mix-and-match' clinical trial testing Moderna's vaccine as booster shot

Shares of Moderna Inc. were down 0.2% in premarket trading on Wednesday after it announced a deal with Unicef to supply 34 million doses of its COVID-19 vaccine in the fourth quarter of 2021 and up to 466 million doses of its mRNA shot in 2022. Moderna's stock is up 76.7% for the year, while the broader S&P 500 has gained 11.8%.

Moderna signs deal to provide up to 466 million doses of its COVID-19 shot to Unicef

CAMBRIDGE, Mass.--(BUSINESS WIRE)--UNICEF and Moderna announce long term agreement to supply vaccine on behalf of the COVAX facility.

UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

Moderna Inc (NASDAQ: MRNA) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children. It has entered into a deal with Lonza Group (OTC: LZAGF) for a new drug substance production line in Geleen, Netherlands, which will have the capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.

Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses

Thermo Fisher Scientific

Moderna Inc (NASDAQ: MRNA) entered into an agreement with Thermo Fisher Scientific Inc (NYSE: TMO) for manufacturing and packaging its COVID-19 vaccine, as Moderna looks to scale up production. Thermo Fisher Scientific will provide fill-finish, labeling, and packaging services for Moderna's mRNA vaccine at Thermo Fisher's commercial manufacturing site in Greenville, North Carolina.

Moderna Taps Thermo Fisher to Help Scale Up COVID-19 Vaccine Production

The pandemic isn't over yet -- even in the U.S.

This Ominous Warning From Moderna Could Shake Up the COVID Vaccine Market

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new drug substance production agreement with Lonza in the Netherlands.

Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands

Moderna Inc. said late Tuesday it has hammered out an agreement with Thermo Fisher Scientific for the manufacturing, labeling and packing of Moderna's COVID-19 vaccine at a Thermo Fisher plant in North Carolina. The agreement aims "to leverage manufacturing capacity to continue to drive global supply of vaccines," the company said.

News for Moderna Stock (MRNA)